Who is sponsoring NCT05234112?

NCT05234112 is sponsored by University Medical Center Groningen.

What drugs are being tested in NCT05234112?

Interventions in NCT05234112: Community mobilisation for hrHPV self-testing, hrHPV self-testing, Follow-up after testing, VIA, Thermo-ablation or cryotherapy for dysplasia, Pap smear cytology.

What condition does NCT05234112 study?

NCT05234112 studies HPV Infection, Cervix Cancer, Cervical Dysplasia.

Is NCT05234112 still recruiting?

NCT05234112 is currently completed. Last updated 22 February 2024.

Last reviewed 2024-02-22 · How we verify

NCT05234112: PRESCRIP-TEC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention and Screening Towards Elimination of Cervical Cancer

Completed NA Last updated 22 February 2024

What this trial tests

NA trial testing Community mobilisation for hrHPV self-testing in HPV Infection in 30,000 participants. Completed in 31 January 2024.

Timeline

15 September 2022

Primary endpoint
30 December 2023

31 January 2024

Quick facts

Lead sponsor	University Medical Center Groningen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	30,000
Start date	15 September 2022
Primary completion	30 December 2023
Estimated completion	31 January 2024
Sites	1 location across Uganda

Drugs / interventions tested

Community mobilisation for hrHPV self-testing
hrHPV self-testing
Follow-up after testing
VIA
Thermo-ablation or cryotherapy for dysplasia
Pap smear cytology

Conditions studied

HPV Infection — all drugs for HPV Infection →
Cervix Cancer — all drugs for Cervix Cancer →
Cervical Dysplasia — all drugs for Cervical Dysplasia →

Sponsor

University Medical Center Groningen

Who can join

Adults 30 to 60, female only, with HPV Infection or Cervix Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The research project applies the protocol of the World Health Organisation for screening of cervical cancer, with testing of hrHPV as first screening, followed by Visual Inspection of the cervix with Acetic Acid for hrHPV-positive women and for women with minor lesions thermo-ablation of affected areas. This procedure is applied in Uganda, India and Bangladesh. In Slovakia hrHPV-positive women are offered Pap-smear and for women with Pap IV lis excision.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Investigating feasibility of 2021 WHO protocol for cervical cancer screening in underscreened populations: PREvention and SCReening Innovation Project Toward Elimination of Cervical Cancer (PRESCRIP-TEC).
Sultanov M, Zeeuw J, Koot J, der Schans JV, et al · · 2022 · cited 15× · PMID 35840949 · DOI 10.1186/s12889-022-13488-z
Cervical high-risk human papillomavirus infection and its associated risk factors: a community-based cross-sectional study in hard-to-reach areas in Bangladesh.
Nazrul N, Rahman A, de Fouw M, Campbell C, et al · · 2025 · PMID 41412622 · DOI 10.1136/bmjopen-2025-103915

Verify or expand the search:

Other recruiting trials for HPV Infection

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
NCT06507917 — Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for · NA · recruiting
NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
NCT06959563 — Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV · EARLY_PHASE1 · active not recruiting

Other University Medical Center Groningen trials

Trials by the same sponsor.

NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05234112 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
Last refreshed: 22 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05234112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing